1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Aliqopa

Aliqopa

  • January 2019
  • 18 pages
  • ID: 5780244
  • Format: PDF
  • By Pharma Intelligence

Summary

Table of Contents

Drug Overview
Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal B-cell development, and is subverted by follicular lymphoma (FL) to promote survival and growth. The p110-delta subunit is particularly important for the survival of indolent NHLs, and p110-delta as well as p110-alpha are hypothesized to be important for the survival of aggressive NHLs.
With the accelerated approval of Aliqopa for the third-line treatment of FL, Bayer positioned its PI3K inhibitor in direct competition with Zydelig (idelalisib; Gilead), the first PI3K inhibitor approved for FL. Bayer is also investigating Aliqopa in earlier lines of treatment and as a combination therapy with rituximab in the pivotal Phase III CHRONOS-2 (ClinicalTrials.gov identifier: NCT02369016), CHRONOS-3 (ClinicalTrials.gov identifier: NCT02367040), and CHRONOS-4 (ClinicalTrials.gov identifier: NCT02626455) trials.

Analyst Outlook
With the accelerated approval of Aliqopa (copanlisib; Bayer) for the third-line treatment of follicular lymphoma (FL), Bayer positioned its phosphoinositide 3-kinase (PI3K) inhibitor in direct competition with Zydelig (idelalisib; Gilead), the first PI3K inhibitor approved for FL. Bayer is also investigating Aliqopa in earlier lines of treatment and as a combination therapy with rituximab in the pivotal Phase III CHRONOS-2 (ClinicalTrials.gov identifier: NCT02369016), CHRONOS-3 (ClinicalTrials.gov identifier: NCT02367040), and CHRONOS-4 (ClinicalTrials.gov identifier: NCT02626455) trials. Indication for use with standard-therapy rituximab and expansion into earlier treatment settings would give Aliqopa an advantage over Zydelig, which failed to move beyond its single approval in third-line FL. In addition, Aliqopa may have to compete with PI3K inhibitors Copiktra (duvelisib; Verastem/Infinity/Yakult Honsha Co), INCB050465 (Incyte), and umbralisib (TG Therapeutics), which are currently in late-phase development for FL. However, Aliqopa’s commercial outlook in this indication may surpass other PI3K inhibitors due to its range of activity. Aliqopa is the only drug in its class that is a strong inhibitor of PI3K-alpha in addition to PI3K-delta, which could prove useful as PI3K-alpha is hypothesized to play a more prominent role as indolent non-Hodgkin’s lymphomas (NHLs) become more aggressive.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2019’; Interleukin ...

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H2 ...

Toll Like Receptor 4 - Pipeline Review, H2 2019

Toll Like Receptor 4 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Toll Like Receptor 4 - Pipeline Review, H2 2019SummaryToll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on